STIFEL 2026 HEALTHCARE CONFERENCE - AN2 THERAPEUTICS INC

Financial Performance:

• The company holds $80 million in cash on hand, which is sufficient to fund operations through 2029 and support the execution of three Phase 2 clinical readouts expected in the coming year.
• Management describes the company as "capital efficient," with the current financial runway covering the development of all active programs and preclinical initiatives.
• Specific revenue figures, profit margins, or debt levels were not disclosed, as the company remains in clinical development stages prior to commercialization.

Guidance and Future Outlook:

• A Phase 2 trial for Petroborol in Polycythemia Vera (PV) is set to initiate immediately, with top-line efficacy data anticipated in the second half of 2027.
• Top-line data for the Phase 2 investigation of Petroborol in NTM-MAC is expected in 2027, while the Phase 2 data for M. abscessus is targeted for disclosure in 2027 as well.
• Phase 2 data for the Chagas disease program is projected for release in the second half of 2027, with a focus on 4-month follow-up metrics.
• The company plans to advance the ENPP1 candidate for Hypophosphatasia (HPP) rapidly, following the recent identification of a development candidate.

Business Segments and Product Lines:

• Petroborol (PV Program): An oral, red-cell-specific inhibitor targeting a novel mechanism on the globin side (distinct from current injectable hepcidin agents) to maintain hematocrit below 45% in phlebotomy-dependent patients. The Phase 2 trial design includes a 10-patient sentinel phase, a 28-week Part 1 for dose-ranging, a randomized Part 2 for efficacy confirmation, and an extension Part 3 for durability.
• Petroborol (NTM Program): An anti-infective asset with two active investigations: a Phase 2 for treatment-refractory MAC (where prior data showed the drug is 250x more potent against M. abscessus than MAC) and a Phase 2 for M. abscessus, targeting an unmet need in a population with high mortality and no FDA-approved oral therapies.
• Chagas Disease Program: An anti-parasitic targeting CPSF3 (the same mechanism as the recently approved African sleeping sickness drug Cozibor), aiming to provide a single-dose curative profile. Preclinical data shows sterilization in non-human primates naturally infected in Texas.
• Preclinical Pipeline: Includes ENPP1 inhibitors for oncology (making "cold tumors hot") and rare bone disease (HPP), a Phase 2-ready PI3K program (acquired from Anacor) targeting pan-mutant inhibition to address a gap in the current landscape, and PI4K assets.
• HPP Opportunity: The company has developed a specific oral candidate for Hypophosphatasia, positioning itself against injectable enzymatic replacements and leveraging a validated mechanism.

Market and Competitive Landscape:

• PV Space: Petroborol differentiates from approved (e.g., Respiratide) and late-stage competitors (e.g., hepcidin modulators) by being oral, having a unique mechanism (globin vs. heme/iron starvation), and offering red-blood-cell specificity without affecting platelets or white blood cells.
• Anti-infectives: Petroborol targets a massive unmet need in M. abscessus and MAC, where current standard-of-care involves burdensome, multi-drug IV regimens. The company notes strong interest from strategics like Merck, GSK, and J&J in this sector.
• Oncology: The PI3K space is crowded, but Petroborol's specific design aims for true pan-mutant inhibition over wild-type differentiation, addressing the low survival rates seen with current kinase-specific inhibitors.
• Rare Diseases: Both PV and NTM are orphan indications, suggesting similar pricing precedents to drugs like Arca and Resveratide; management anticipates potential partnership opportunities to commercialize both indications.

Risks and Challenges:

• Clinical Execution: The PV trial relies on translating observed hematocrit reduction into formal Phase 2 efficacy endpoints; failure to demonstrate reduced phlebotomy frequency could hinder progression.
• Regulatory Pathways: The Chagas program requires validation of patient-reported outcomes (PROs) and specific parasitology endpoints (similar to Hepatitis C SVR) before Phase 3 initiation.
• Target Validation: The ENPP1 target in oncology remains unvalidated in humans, though recent data from Riva Sciences in colorectal cancer is viewed as a positive catalyst for this asset class.
• Competition: Multiple competitors exist in the PV, PI3K, and anti-NTM spaces, requiring robust differentiation in mechanism and convenience (oral vs. injectable) to gain market share.

Management Commentary and Tone:

• CEO Eric Giesem expressed high confidence, describing the company as having its "robust pipeline" and being "stronger as a company now that we've matured."
• The tone is optimistic yet scientifically grounded, emphasizing the de-risking of the Chagas and HPP programs through successful preclinical models and parallel approvals (Cozibor).
• Management highlighted the flexibility of the Petroborol platform, noting its potential for broad use cases across disparate rare diseases and its unique boron chemistry which avoids freedom-to-operate (FTO) IP issues.

Analyst Questions and Answers:

• Q: How does Petroborol differentiate from injectable hepcidin agents?
  • A: Petroborol is oral, has a distinct mechanism (globin side vs. iron starvation), and is highly red-cell specific, avoiding impacts on platelets and white blood cells.
• Q: What are the data disclosure timelines for the PV trial?
  • A: First patient dose this year; sentinel data expected in Q1 2027; efficacy data cuts (dose confirmation and phlebotomy reduction) anticipated mid-to-late 2027 (10-15 patients).
• Q: Is background cytoreductive therapy required in the PV trial?
  • A: The trial allows patients to remain on hydroxyurea (used by ~25% of PV patients); future combination with injectable agents is a potential option for refractory cases, though oral monotherapy is the primary goal.
• Q: How will the Chagas program be commercialized?
  • A: Similar to Hepatitis C, it requires a heavy "test and treat" implementation effort; management believes the program may be best suited for a larger company with the resources to drive diagnostic and awareness campaigns.
• Q: What defines success for the M. abscessus Phase 2?
  • A: Improvement in culture conversion (bacteria clearance) and patient-reported outcomes regarding quality of life/respiratory symptoms; Paratech's ~20-point improvement in culture conversion serves as a benchmark.

Other Key Points:

• Boron Chemistry: The company emphasized the uniqueness of its boron chemistry, which enables targeting of novel proteins like CPSF3 (Chagas/HPP) and ENPP1, with no known FTO issues.
• Cozibor Precedent: The approval of Cozibor (also a boron-based drug) for African sleeping sickness validates the company's ability to achieve 96% curative rates with a single-dose oral regimen, de-risking the Chagas program.
• Strategic Partnerships: While the company remains independent with sufficient cash, management hinted at the likelihood of partnering for the commercialization of the Chagas and potentially PV/NTM assets due to the required implementation scale.